Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations"

Morley, K. I. and Hall, W. D. (2004) Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations". Journal of Molecular Medicine- JMM, 82 1: 21-30. doi:10.1007/s00109-003-0496-x


Author Morley, K. I.
Hall, W. D.
Title Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations"
Journal name Journal of Molecular Medicine- JMM   Check publisher's open access policy
ISSN 0946-2716
Publication date 2004-01-01
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1007/s00109-003-0496-x
Volume 82
Issue 1
Start page 21
End page 30
Total pages 10
Place of publication Berlin / Heidelberg
Publisher Springer-Verlag
Collection year 2004
Language eng
Subject C1
380103 Biological Psychology (Neuropsychology, Psychopharmacology, Physiological Psychology)
730307 Health policy evaluation
170101 Biological Psychology (Neuropsychology, Psychopharmacology, Physiological Psychology)
160508 Health Policy
Abstract Current pharmacotherapies for psychiatric disorders are generally incompletely effective. Many patients do not respond well or suffer adverse reactions to these drugs, which can result in poor patient compliance and poor treatment outcome. Adverse drug reactions and non-response are likely to be influenced by genetic polymorphisms. Pharmacogenetics holds some promise for improving the treatment of mood disorders by utilising information about genetic polymorphisms to match patients to the drug therapy that is the most effective with the fewest side effects. Pharmacogenomics promises to facilitate the development of new drugs for treatment. However, these technologies raise many ethical, economic and regulatory issues that need to be addressed before they can be integrated into psychiatry, and medicine more generally. We discuss ethical and policy issues arising from pharmacogenetic testing and pharmacogenomics research, such as informed consent, privacy and confidentiality, research on vulnerable persons and discrimination; and economic viability of pharmacogenetics and pharmacogenomics. We conclude with recommendations for the regulation and distribution of pharmacogenetic testing services and pharmacogenomic drugs.
Keyword Medicine, Research & Experimental
Pharmacogenetics
Pharmacogenomics
Bioethical Issues
Socioeconomic Factors
Psychopharmacology
Drug Discovery
Informed Consent
Health-care
Genetics
Medicine
Future
Therapy
Privacy
Issues
Antidepressant
Genetics & Heredity
Socioeconomic
Factors
Q-Index Code C1
Additional Notes This document is a journal review.

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Excellence in Research Australia (ERA) - Collection
2005 Higher Education Research Data Collection
School of Public Health Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 18 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 25 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 15 Aug 2007, 14:30:50 EST